Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. - Université de Bretagne Occidentale Access content directly
Journal Articles Journal of Clinical Oncology Year : 2016

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Holly Geyer
  • Function : Author
Robyn Scherber
  • Function : Author
Heidi Kosiorek
  • Function : Author
Amylou C Dueck
  • Function : Author
Zhijian Xiao
  • Function : Author
Stefanie Slot
  • Function : Author
Sonja Zweegman
  • Function : Author
Federico Sackmann
  • Function : Author
Ana Kerguelen Fuentes
  • Function : Author
Dolores Hernández-Maraver
  • Function : Author
Konstanze Döhner
  • Function : Author
Claire N Harrison
  • Function : Author
Deepti Radia
  • Function : Author
Pablo Muxi
  • Function : Author
Carlos Besses
  • Function : Author
Francisco Cervantes
  • Function : Author
Peter L Johansson
  • Function : Author
Bjorn Andreasson
  • Function : Author
Tiziano Barbui
  • Function : Author
Karin Bonatz
  • Function : Author
Andreas Reiter
  • Function : Author
Dana Ranta
  • Function : Author
Lydia Roy
  • Function : Author
Jean-Yves Cahn
  • Function : Author
Norman Maldonado
  • Function : Author
Giovanni Barosi
  • Function : Author
Robert Peter Gale
  • Function : Author
Yue Zhang
  • Function : Author
Xiujuan Sun
  • Function : Author
Peter a W Te Boekhorst
  • Function : Author
Suzan Commandeur
  • Function : Author
Harry Schouten
  • Function : Author
Heike L Pahl
  • Function : Author
Martin Griesshammer
  • Function : Author
Frank Stegelmann
  • Function : Author
Thomas Lehmann
  • Function : Author
Zhenya Senyak
  • Function : Author
Alessandro M Vannucchi
  • Function : Author
Francesco Passamonti
Jan Samuelsson
  • Function : Author
Ruben A Mesa
  • Function : Author

Abstract

Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present.

Dates and versions

hal-01276589 , version 1 (19-02-2016)

Identifiers

Cite

Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C Dueck, Jean-Jacques Kiladjian, et al.. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.. Journal of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩. ⟨hal-01276589⟩
1719 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More